Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

230
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
230
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

379
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
379
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

279
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
279

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Machine learning to predict venous thrombosis in acutely ill medical patients.

Research and practice in thrombosis and haemostasis·2020
Same author

Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.

JAMA cardiology·2020
Same author

Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation.

Journal of thrombosis and thrombolysis·2020
Same author

Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.

Journal of the American College of Cardiology·2020
Same author

The AngelMed Guardian<sup>®</sup> System in the Detection of Coronary Artery Occlusion: Current Perspectives.

Medical devices (Auckland, N.Z.)·2020
Same author

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.

Nature reviews. Cardiology·2020

相关实验视频

Updated: Feb 27, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.9K

贝叶斯机器学习模型指导代,个性化抗凝剂剂量决策:ENGAGE AF-TIMI 48试验分析

C Michael Gibson1, Cathy Chen2, Jacqueline Buros-Novik3

  • 1Baim Institute for Clinical Research, Harvard Medical School, Boston, Massachusetts, USA.

JACC. Advances
|February 26, 2026
PubMed
概括

一个新的贝叶斯式机器学习模型,Adele,通过预测风险并根据个人对中风,出血和死亡的偏好优化edoxaban剂量,为心房患者提供个性化的抗凝药. 与标准方法相比,这种方法可以提高风险预测的准确性.

关键词:
人工智能的人工智能是人工智能.心房动是心房动的一种.这是一种直接的口服抗凝剂.埃多克萨班 (EDOXABAN) 是一种患者的中心性.药物动力学 药物动力学

更多相关视频

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

相关实验视频

Last Updated: Feb 27, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.9K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

科学领域:

  • 心血管医学 心血管医学
  • 医疗保健中的机器学习
  • 药物指标 (Pharmacometrics) 是一个指标.

背景情况:

  • 目前用于心房的抗凝药使用固定的剂量,忽视患者对中风,出血和死亡等风险的特定偏好.
  • 需要个性化治疗策略,以优化心房的抗凝治疗.

研究的目的:

  • 开发和评估Adele,这是贝叶斯的机器学习模型,用于在心房患者中个性化,长期的抗凝剂剂量.
  • 将患者对中风,出血和死亡风险的偏好纳入剂量决策.

主要方法:

  • 开发了Adele,贝叶斯竞争风险,多状态危险模型,训练了来自ENGAGE AF-TIMI 48试验的5380名edoxaban治疗心房的患者.
  • 利用患者的药理动力学 (PK) 和基线数据进行个性化,持续的风险预测.
  • 将Adele的预测准确度与使用一致性索引的标准Kaplan-Meier估计器进行了比较.

主要成果:

  • 阿德尔的预测准确度高于卡普兰-梅尔估计器,改善了对心血管死亡 (+12.1%),残疾 (+11.8%),主要胃肠道出血 (+13.7%) 和缺血性中风 (+3.3%) 的三年预测.
  • 该模型显示动态风险预测,调整事件发生后的事件概率,如内出血或缺血性中风.
  • 患者示例说明了阿德尔能够根据不同的假设结果偏好确定最佳的edoxaban剂量 (15mg,30mg,60mg).

结论:

  • 阿德尔是一个先进的贝叶斯框架,整合了临床因素和PK数据,用于适应性,以患者为中心,偏好加权的预测.
  • 该模型通过动态调整预测并指导最佳剂量,使个性化抗凝管理成为可能.